Search - tctmd.com

Displaying 641 - 660 of 1259

Sort: Relevancy | Date

News Daily News

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Shelley Wood

May 03, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Daily News

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Shelley Wood

April 24, 2017

News Daily News

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Michael O'Riordan

April 18, 2017

Presentation

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

April 18, 2017

News Daily News

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

Yael L. Maxwell

April 17, 2017

News Opinion Fellow Talk

The Left Main Debate: What Does it Mean for the Future of Intervention?

Tiffany Patterson, MBBS

April 12, 2017

News Daily News

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

Michael O'Riordan

April 11, 2017

Presentation Fellows 2017

The Evolution of Drug-Eluting Stents

Presenter: Ajay J. Kirtane

April 07, 2017

News Industry News

REVA Receives CE Mark for Fantom

April 04, 2017

News Daily News

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

Michael O'Riordan

March 29, 2017

News Conference News ACC 2017

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

Michael O'Riordan

March 18, 2017

News Features

The Numbers Game: Door-to-Balloon or First Medical Contact? STEMI Care Still Needs Work Nationwide

L.A. McKeown

March 16, 2017

News Conference News ACC 2017

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Michael O'Riordan

March 10, 2017

News Daily News

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

Todd Neale

March 07, 2017

News Daily News

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Todd Neale

March 06, 2017

News Conference News CRT 2017

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

Michael O'Riordan

February 21, 2017

News Daily News

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

Michael O'Riordan

February 16, 2017

News Daily News

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Michael O'Riordan

February 13, 2017

Presentation

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

February 13, 2017

Advertisement

Absorb BVS Recalled in Australia From All Centers Not Studying Device

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

Long-term MI Risk Among Stable CAD Patients: Some Clues From CORONOR

Absorb Comparable to Xience in Economic Analysis, but BVS Safety Concerns Could Alter Balance

Economic Outcomes of Absorb BVSvs Everolimus-Eluting Stents in PCI

Treating In-Stent CTOs May Be Riskier Than De Novo CTOs Despite Similar Procedural Success

The Left Main Debate: What Does it Mean for the Future of Intervention?

ICTUS: No Benefit at 10 Years With Early Invasive Strategy in NSTE ACS Patients

The Evolution of Drug-Eluting Stents

REVA Receives CE Mark for Fantom

Scaffold Thrombosis Concerns With Absorb BVS Echoed in AIDA Trial

ABSORB III: Two-Year Results Show a Higher MACE Rate Compared With Xience

The Numbers Game: Door-to-Balloon or First Medical Contact? STEMI Care Still Needs Work Nationwide

Low HDL Cholesterol Common in Young MI Patients, With Young Women Faring Worse Long-Term

Faster Primary PCIs Linked to Higher Stent Thrombosis Risk With Bivalirudin

FDA Gives Thumbs Up to Side Branch Stent for Bifurcation Lesions

Absorb BVS: Better Technique, Better Outcomes? More Data—and More Debate

DESolve Bioresorbable Stent Compares Well With Absorb, but Longer Follow-up Needed

‘Misalignment’ Exists Between What Concerns Patients and Physicians Most After PCI

Beyond Restenosis: Patients’ Preference for Drug-Eluting or Bare-Metal Stents

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content